Investors > News Releases
Sep 10, 2020
Myriad Genetics Expands Board of Directors with New Member
Corporate
Aug 21, 2020
American Society of Clinical Oncology Exclusively Cites myChoice® CDx in New Recommendations for Patients with Advanced Ovarian Cancer
Pipeline
Aug 14, 2020
Myriad Genetics Announces Inducement Awards
Corporate
Aug 13, 2020
Myriad Genetics Appoints Paul J. Diaz as President and Chief Executive Officer and a Member of the Board of Directors
Corporate
Aug 13, 2020
Myriad Genetics Reports Fiscal Fourth-Quarter 2020 Financial Results
Financial
Aug 10, 2020
New Study Shows Screening Based on Self-Reported Ethnicity Fails to Identify Significant Percentage of Pregnancies Affected by Serious Genetic Conditions
Pipeline
Aug 06, 2020
Myriad to Announce Fiscal Fourth-Quarter and Full Fiscal Year 2020 Financial Results on August 13, 2020
Corporate
Jul 31, 2020
Medicare Expands Coverage for BRACAnalysis® CDx in Prostate Cancer
Pipeline
Jul 29, 2020
Myriad Launches Proprietary AMPLIFY™ Technology, Further Increasing the Performance of its Prequel™ NIPS Test
Pipeline
Jul 28, 2020
Myriad Announces the Launch of a New Radiographic Progression Prognostic Tool, Adding to Clinical Value of Vectra®
Pipeline
Jul 22, 2020
Myriad Genetics Expands Board of Directors with New Member and Announces Upcoming Retirement of Walter (Wally) Gilbert, Ph.D.
Corporate
Jul 07, 2020
Myriad Announces New Studies Validating the Ability of Myriad’s riskScore® Test to Modify Breast Cancer Risk Prediction
Products
Jul 06, 2020
Myriad Announces Partnership with OptraHEALTH® to Deliver “Gene™” a New AI Based Information Tool for Hereditary Cancer Patients
Products
Jul 01, 2020
Myriad Launches New GeneSight® Psychotropic Patient Collection Kit
Products
Jun 25, 2020
New Study Demonstrates the Ability of myPath® Melanoma to Accurately Classify Lesions Ruled Indeterminate by Standard Pathological Assessment
Pipeline